178 related articles for article (PubMed ID: 36078050)
1. Desialylated Mesenchymal Stem Cells-Derived Extracellular Vesicles Loaded with Doxorubicin for Targeted Inhibition of Hepatocellular Carcinoma.
Yang C; Guan Z; Pang X; Tan Z; Yang X; Li X; Guan F
Cells; 2022 Aug; 11(17):. PubMed ID: 36078050
[TBL] [Abstract][Full Text] [Related]
2. Lactoferrin-modified PEGylated liposomes loaded with doxorubicin for targeting delivery to hepatocellular carcinoma.
Wei M; Guo X; Tu L; Zou Q; Li Q; Tang C; Chen B; Xu Y; Wu C
Int J Nanomedicine; 2015; 10():5123-37. PubMed ID: 26316745
[TBL] [Abstract][Full Text] [Related]
3. Extracellular Vesicles-Encapsulated MicroRNA-125b Produced in Genetically Modified Mesenchymal Stromal Cells Inhibits Hepatocellular Carcinoma Cell Proliferation.
Baldari S; Di Rocco G; Magenta A; Picozza M; Toietta G
Cells; 2019 Dec; 8(12):. PubMed ID: 31816923
[TBL] [Abstract][Full Text] [Related]
4. Bone mesenchymal stem cells derived extracellular vesicles promote TRAIL-related apoptosis of hepatocellular carcinoma cells via the delivery of microRNA-20a-3p.
Deng L; Wang C; He C; Chen L
Cancer Biomark; 2021; 30(2):223-235. PubMed ID: 33136092
[TBL] [Abstract][Full Text] [Related]
5. Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma.
Pranatharthiharan S; Patel MD; Malshe VC; Pujari V; Gorakshakar A; Madkaikar M; Ghosh K; Devarajan PV
Drug Deliv; 2017 Nov; 24(1):20-29. PubMed ID: 28155331
[TBL] [Abstract][Full Text] [Related]
6. Ligand-directed reduction-sensitive shell-sheddable biodegradable micelles actively deliver doxorubicin into the nuclei of target cancer cells.
Zhong Y; Yang W; Sun H; Cheng R; Meng F; Deng C; Zhong Z
Biomacromolecules; 2013 Oct; 14(10):3723-30. PubMed ID: 23998942
[TBL] [Abstract][Full Text] [Related]
7. Liposomes for targeting hepatocellular carcinoma: use of conjugated arabinogalactan as targeting ligand.
Shah SM; Goel PN; Jain AS; Pathak PO; Padhye SG; Govindarajan S; Ghosh SS; Chaudhari PR; Gude RP; Gopal V; Nagarsenker MS
Int J Pharm; 2014 Dec; 477(1-2):128-39. PubMed ID: 25311181
[TBL] [Abstract][Full Text] [Related]
8. Collaborative assembly of doxorubicin and galactosyl diblock glycopolymers for targeted drug delivery of hepatocellular carcinoma.
Li J; Zhang Y; Cai C; Rong X; Shao M; Li J; Yang C; Yu G
Biomater Sci; 2020 Jan; 8(1):189-200. PubMed ID: 31821399
[TBL] [Abstract][Full Text] [Related]
9.
Sun R; Fang L; Lv X; Fang J; Wang Y; Chen D; Wang L; Chen J; Qi Y; Tang Z; Zhang J; Tian Y
Drug Deliv; 2021 Dec; 28(1):2071-2084. PubMed ID: 34595970
[TBL] [Abstract][Full Text] [Related]
10. Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma.
Zhou X; Zhang M; Yung B; Li H; Zhou C; Lee LJ; Lee RJ
Int J Nanomedicine; 2012; 7():5465-74. PubMed ID: 23093902
[TBL] [Abstract][Full Text] [Related]
11. The role of extracellular vesicles in mediating progression, metastasis and potential treatment of hepatocellular carcinoma.
Yang N; Li S; Li G; Zhang S; Tang X; Ni S; Jian X; Xu C; Zhu J; Lu M
Oncotarget; 2017 Jan; 8(2):3683-3695. PubMed ID: 27713136
[TBL] [Abstract][Full Text] [Related]
12. Functional Doxorubicin-Loaded Omega-3 Unsaturated Fatty Acids Nanoparticles in Reversing Hepatocellular Carcinoma Multidrug Resistance.
Wang C; Wei X; Shao G
Med Sci Monit; 2021 Feb; 27():e927727. PubMed ID: 33524008
[TBL] [Abstract][Full Text] [Related]
13. Intravenously transplanted mesenchymal stromal cells: a new endocrine reservoir for cardioprotection.
Huang A; Liu Y; Qi X; Chen S; Huang H; Zhang J; Han Z; Han ZC; Li Z
Stem Cell Res Ther; 2022 Jun; 13(1):253. PubMed ID: 35715868
[TBL] [Abstract][Full Text] [Related]
14. Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence.
Zhang F; Jia Y; Zheng X; Shao D; Zhao Y; Wang Z; Dawulieti J; Liu W; Sun M; Sun W; Pan Y; Cui L; Wang Y; He K; Zhang M; Li J; Dong WF; Chen L
Acta Biomater; 2019 Dec; 100():352-364. PubMed ID: 31563690
[TBL] [Abstract][Full Text] [Related]
15. Reductively degradable α-amino acid-based poly(ester amide)-graft-galactose copolymers: facile synthesis, self-assembly, and hepatoma-targeting doxorubicin delivery.
Lv J; Sun H; Zou Y; Meng F; Dias AA; Hendriks M; Feijen J; Zhong Z
Biomater Sci; 2015 Jul; 3(7):1134-46. PubMed ID: 26221946
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin and paclitaxel co-bound lactosylated albumin nanoparticles having targetability to hepatocellular carcinoma.
Thao LQ; Lee C; Kim B; Lee S; Kim TH; Kim JO; Lee ES; Oh KT; Choi HG; Yoo SD; Youn YS
Colloids Surf B Biointerfaces; 2017 Apr; 152():183-191. PubMed ID: 28110040
[TBL] [Abstract][Full Text] [Related]
17. Surface Engineering of HEK293 Cell-Derived Extracellular Vesicles for Improved Pharmacokinetic Profile and Targeted Delivery of IL-12 for the Treatment of Hepatocellular Carcinoma.
Zhang J; Song H; Dong Y; Li G; Li J; Cai Q; Yuan S; Wang Y; Song H
Int J Nanomedicine; 2023; 18():209-223. PubMed ID: 36660339
[TBL] [Abstract][Full Text] [Related]
18. Extracellular-vesicles delivered tumor-specific sequential nanocatalysts can be used for MRI-informed nanocatalytic Therapy of hepatocellular carcinoma.
Wu H; Xing H; Wu MC; Shen F; Chen Y; Yang T
Theranostics; 2021; 11(1):64-78. PubMed ID: 33391461
[No Abstract] [Full Text] [Related]
19. GRP78-targeted ferritin nanocaged ultra-high dose of doxorubicin for hepatocellular carcinoma therapy.
Jiang B; Zhang R; Zhang J; Hou Y; Chen X; Zhou M; Tian X; Hao C; Fan K; Yan X
Theranostics; 2019; 9(8):2167-2182. PubMed ID: 31149036
[TBL] [Abstract][Full Text] [Related]
20. Extracellular vesicles: Natural liver-accumulating drug delivery vehicles for the treatment of liver diseases.
Zhang G; Huang X; Xiu H; Sun Y; Chen J; Cheng G; Song Z; Peng Y; Shen Y; Wang J; Cai Z
J Extracell Vesicles; 2020 Dec; 10(2):e12030. PubMed ID: 33335695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
